This is an important recognition for the entire team and for Swedish life science. We have built Encare over many years in close collaboration with the ERAS® Society, and this award shows that our work is now making an impact where it matters most – among hospitals and healthcare systems facing capacity constraints, waiting lists and rising costs. The fact that the jury specifically highlights our US reference customers and our business model is a strong external validation of the direction we have chosen

Working with Mayo Clinic Platform _Solutions Studio has enabled us to validate that our solution can be implemented and sustained in one of the world’s most advanced healthcare environments. This collaboration reinforces the importance of structured measurement, benchmarking, and governance in delivering consistently high-quality perioperative care for patients.

This collaboration with Mayapada Healthcare represents a landmark step for ERAS® in Indonesia. Mayapada Healthcare’s strong commitment to quality and innovation makes them an ideal partner. Together, we will establish new standards for enhanced recovery and significantly improve outcomes for orthopedic patients across the country.

Being qualified by Mayo Clinic Platform is the ultimate recognition of the value and quality of EIAS. It validates that our solution meets the highest standards for improving surgical outcomes, and it gives us a unique opportunity to accelerate ERAS® adoption in the U.S. and globally.

Working with Mayo Clinic Platform speeds up digital healthcare innovation. It gives digital health companies the tools, data, and capabilities they need to more efficiently and effectively develop and deploy AI and data-centric solutions. When a solution is qualified, providers can trust it has been reviewed for adherence to responsible AI principles, all aimed at supporting care teams and improving patient outcomes.

ERAS® works best when implemented consistently and hospital-wide. This expansion reflects the Jewish General Hospital’s commitment to clinical excellence and the value of evidence-based perioperative care. We are honored to continue supporting the JGH – and all of our valued partners – as they lead the way in implementing structured ERAS® pathways across all major surgical areas.

We are honored to be selected for Health 3-2-1 and see tremendous potential in the U.S. market. With the growing emphasis on surgical quality improvement and enhanced recovery protocols, we believe our solutions can play a pivotal role in improving patient outcomes and hospital efficiency across the U.S. This selection is also an important step in our accelerated U.S. expansion, reinforcing our commitment to bringing evidence-based ERAS® solutions to more healthcare providers nationwide.

We are honored to support the National Cancer Institute of Ukraine in advancing surgical care during such a critical time. Through this partnership, we aim to equip NCI with the tools and knowledge needed to optimize patient recovery and set a benchmark for ERAS® implementation across Ukraine.

This expansion demonstrates Karolinska University Hospital’s dedication to advancing evidence-based, patient-centered care. We’re proud to contribute with EIAS, empowering clinical teams to deliver even better outcomes and patient experiences. This aligns perfectly with our vision of driving progress in evidence-based care.

We are proud that our collaboration with Sykehuset Østfold has not only led to improved patient outcomes but also to significant economic savings. Through our solutions, EIAS and EIP, the hospital has been able to analyze its data and optimize routines in line with evidence to reduce complications and improve resource efficiency.

We are deeply honored to receive this recognition from Techarenan Challenge 2024. This nomination not only highlights our commitment to advancing healthcare but also provides an opportunity to showcase how our innovations contribute to improving healthcare and patient recovery processes. We look forward to presenting our work and connecting with industry leaders.

We are incredibly honored by this recognition from Rise Europe. This nomination reflects our longstanding commitment to advancing healthcare through technology and evidence. Our work with the overall ERAS® concept and ERAS® protocols represents our core mission to enhance patient outcomes and improve healthcare practices. Looking ahead, we are eager to further innovate in healthcare technology, setting new benchmarks in patient care and efficiency.

We are very excited to have Lotta join our team. I have had the opportunity to work with Lotta in the past and know that Lotta has exactly the skills that Encare needs as we gear up for further expansion. Simultaneously, we are preserving crucial expertise within the company as our current CSO, Marie Monier, transitions into another role with an increased focus on engaging with both our existing and new customers.

We are very happy to have Niklas in our team. With his strategic view of technology and solid experience and competences, he will not only be an important building block in Encare's expansion both geographically and product-wise, but also play a decisive role in meeting our customers' demand for solutions to improve the healthcare workflow.

Thanks to the continued support from our investors, we can continue our expansion and work towards our mission to positively impact the lives of millions of patients undergoing surgery worldwide. By supporting healthcare providers in implementing best practices in surgical care, Encare can contribute to reducing the number of preventable deaths and complications during surgery.

Few have managed to scale up a standard SaaS solution in healthcare globally like we have, which proves the power of Encare's offering

I see great opportunities for Encare to accelerate its growth, and I hope to be able to contribute with my drive and experience in growing companies when Encare is now scaling up.